FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT

An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal flui...

Full description

Saved in:
Bibliographic Details
Main Authors YEDLURI, SIDDHARTHA, NANNAPANENI, VENKAIAH CHOWDARY, ADIBHATLA, KALI SATYA BHUJANGA RAO, APPADWEDULA, VENKATA SATYANARAYANA, PARVATANENI, DURGA MAHESWARI
Format Patent
LanguageEnglish
French
Published 13.09.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like. La présente invention concerne une formulation pharmaceutique orale contenant une quantité efficace de NRC-AN-019, y compris ses sels pharmaceutiquement acceptables et ses polymorphes tels que la forme I, la forme II et la forme III, destinée à améliorer la biodisponibilité attendue pour l'auto-émulsification au contact du liquide gastro-intestinal. L'invention concerne en outre un procédé de préparation d'une solution orale contenant NRC-AN-019 en une concentration efficace pour une meilleure thérapie contre la leucémie myéloïde chronique tel qu'un inhibiteur de la tyrosine kinase BCR-ABL et contre d'autres tumeurs telles que le cancer de la tête et du cou, le cancer de la prostate et équivalents.
Bibliography:Application Number: WO2011IB01842